Calculation of the cut-off and evaluation of the dynamics of natriuretic peptide for optimization the management of comorbid patients with thyrototoxicosis and heart failure
| Autor: | E. V. Pashchenko, A. I. Chesnikova, V. I. Kudinov, V. P. Terentyev, O. E. Kolomatskaya |
|---|---|
| Jazyk: | English<br />Russian |
| Rok vydání: | 2018 |
| Předmět: | |
| Zdroj: | Медицинский вестник Юга России, Vol 9, Iss 4, Pp 73-80 (2018) |
| Druh dokumentu: | article |
| ISSN: | 2219-8075 2618-7876 |
| DOI: | 10.21886/2219-8075-2018-9-4-73-80 |
| Popis: | Objective: to determine the cut-off of natriuretic peptide for optimization dyagnosis heart failure in comorbid patients with thyrotoxicosis, to assess the dynamics of this indicator during therapy.Materials and methods: 111 patients (58,3±5,6 years) were divided into 4 groups. Te main group consisted of 25 patients with CHD, CHF II-III FC and thyrotoxicosis; the 1st group of comparison - 30 patients with CHD and CHF II-III FC, without thyrotoxicosis; the 2nd group — 30 patients with thyrotoxicosis without CHD, the 3rd group - 26 patients with thyrotoxicosis and CHD, with no signs of CHF. Te fnding of thyroid gland, the level of NT-proBNP was estimated at baseline and afer 6 months therapy. A new cut-off NT-proBNP for the diagnosis of CHF in comorbid patients was calculated by using ROC analysis.Results: the high concentration of NT-proBNP was detected in all patients (more then 125 pg/ml), in the 2nd comparison group — 225.5 (180.1, 376.1) pg/ml. Te NT-proBNP values in the patients of the 1st and 3rd comparison groups did not differ signifcantly. Te highest level of NT-proBNP was detected in the main group — 712.1 (434.3, 893.9) pg/ml. A cut-off of this marker for screening CHF in comorbid patients with CHD and thyrotoxicosis was calculated - 556.4 pg/ml (a sensitivity of 72 %, a specifcity of 100 %, an accuracy of 87.2 % (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|